The US FDA's Oncologic Drugs Advisory Committee's 10-3 recommendation for the approval of Emmaus Life Sciences Inc.'s sickle cell disease candidate L-glutamine shows that a strong safety profile and unmet clinical need can overcome questionable imputation methods and a modest showing of efficacy.
This is a strong endorsement for the company's product, as FDA had previously put forth several concerns about the clinical...




